Oslo, Norway, 26 April 2007
Clavis Pharma has continued its planned scale-up during the first quarter 2007 and the reported operating loss of NOK 13.5 million (9.5) was in line with the 2007 full year forecast announced in the interim report for the fourth quarter 2006.
The ELACYT(TM) Clinical Phase II study in metastatic colorectal cancer has received go-ahead from the ethical committee and the study has been initiated at Beatson Oncology Centre in Glasgow. Inclusion of additional sites has been initiated to secure good patient recruitment. As previously announced, the development program in malignant melanoma is being expanded into combination therapy on pre-treated patients.
The combination with Nexavar(TM)(sorafenib) has received favourable opinion from two European ethical committees and approvals from the corresponding health authorities are expected shortly.
Preliminary data from the ongoing ELACYT study in blood cancers was presented at the annual meeting of the American Association for Cancer Research in Los Angeles (AACR), California on 16 April. Initial safety data looks promising and clinical benefit has been reported.
The ongoing Clinical Phase I study in solid tumours with the second drug candidate, CP-4126, is advancing according to plan. Dose escalation with the aim to reach maximum tolerated dose is welln under way and the Phase II program is currently being planned.